Epinephrine is under clinical development by ARS Pharmaceuticals and currently in Phase I for Seasonal Allergic Rhinitis. According to GlobalData, Phase I drugs for Seasonal Allergic Rhinitis have a 91% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Epinephrine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Epinephrine overview
Epinephrine (ARS-1) is under development for the treatment of anaphylaxis caused by severe allergic reactions to medications, insect bites, asthma, urticaria, seasonal allergic rhinitis, food allergy and infectious rhinitis. It is formulated as spray and administered through intranasal route. The drug candidate acts by targeting ADRA, ADRB adrenergic receptors. It is developed based on Intravail technology.
ARS Pharmaceuticals overview
ARS Pharmaceuticals, formerly Silverback Therapeutics, focuses on the discovery, development and commercialization of medicines for the treatment of chronic viral infections, cancer, and other serious diseases. The company is advancing SBT6050 for breast cancer, gastric cancer, and non-small cell lung cancer (NSCLC), SBT6290 for bladder cancer, triple-negative breast cancer (TNBC), and head and neck (H&N) cancer; and SBT8230 for chronic hepatitis B virus. ARS Pharmaceuticals is also advancing pre-clinical candidates for the treatment of solid tumors and liver fibrosis. The company employs its proprietary, ImmunoTAC technology platform to advance the development of its pipeline products. ARS Pharmaceuticals is headquartered in San Diego, California, the US.
For a complete picture of Epinephrine’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Smarter leaders trust GlobalData
Premium Insights Likelihood of Approval and Phase Transition Success Rate Model - Epinephrine in Seasonal Allergic Rhinitis
Premium Insights
The gold standard of business intelligence.
